Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Declines By 7.5%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 20,830,000 shares, a decline of 7.5% from the October 15th total of 22,530,000 shares. Based on an average daily trading volume, of 1,950,000 shares, the days-to-cover ratio is currently 10.7 days.

BioCryst Pharmaceuticals Stock Up 2.1 %

Shares of BioCryst Pharmaceuticals stock opened at $7.21 on Wednesday. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.88. The company has a market capitalization of $1.49 billion, a P/E ratio of -11.82 and a beta of 1.89. The company has a 50 day moving average of $7.68 and a 200 day moving average of $7.20.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.19) earnings per share. As a group, research analysts anticipate that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. CWM LLC raised its position in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares in the last quarter. Signaturefd LLC increased its stake in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,599 shares during the last quarter. Seven Eight Capital LP acquired a new stake in BioCryst Pharmaceuticals during the first quarter worth approximately $57,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares in the last quarter. Finally, Natixis boosted its holdings in shares of BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 9,350 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several research reports. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Finally, JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.67.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.